FSD Pharma Inc. (HUGE)
|52 Week Range||0.618-2.1|
|1y Target Est||-|
|DCF Unlevered||HUGE DCF ->|
|DCF Levered||HUGE LDCF ->|
|Debt / Equity||20.58%||Neutral|
Upgrades & Downgrades
Latest HUGE news
FSD Pharma to Present at Sidoti Virtual Investor Conference May 10-11
8 May 2023
TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of ...
FSD Pharma receives regulatory clearance for proposed Phase 1 clinical trial of multiple sclerosis d...
7 February 2023
FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) told investors it has received a No Objection Letter (NOL) from Health Canada for its proposed Phase 1 clinical trial of LUCID-21-302 (Lucid-MS), a novel drug ca...
FSD Pharma says recruiting underway in Phase 2 Trial of FSD201 for treating chronic pain associated ...
30 January 2023
FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) said recruiting is underway for the Phase 2 clinical trial of FSD-PEA (FSD201) for the treatment of chronic pain associated with idiopathic Mast Cell Activation ...
FSD Pharma submits clinical trial application for its multiple sclerosis treatment candidate Lucid-M...
17 January 2023
FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) announced it has submitted a Clinical Trial Application (CTA) for a planned Phase-1 clinical trial for Lucid-MS, a candidate for the treatment of multiple sclero...
FSD Pharma plans buyback of up to 1.9 million shares to utilize cash reserves
13 January 2023
FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) said its board of directors has approved a share repurchase program that will allow the company to buy back up to 1.9 million of its subordinate Class B voting s...
FSD Pharma incorporates new subsidiary to capitalize on drug development incentives in Australia
9 January 2023
FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) has announced the incorporation of a new subsidiary to capitalize on drug development incentives in Australia. The Toronto-based biopharma firm told investors it...
FSD Pharma announces changes to its board of directors
29 November 2022
FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) has announced the appointments of Dr Lakshmi P. Kotra and Joseph L.
FSD Pharma wins FDA and Health Canada approval for IND for Phase 2 Trial of FSD201 for treating infl...
6 September 2022
FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) revealed that it has received a study may proceed letter for its Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) and no...
FSD Pharma says Lucid Psycheceuticals subsidiary files patent for novel PEA formulations; presents p...
13 July 2022
FSD Pharma (CSE:HUGE, NASDAQ:HUGE) Inc announced that its wholly-owned Lucid Psycheceuticals Inc subsidiary has filed a provisional patent application on novel formulations of palmitoylethanolamide (P...
FSD Pharma submits IND applications to the FDA and Health Canada for Phase 2 clinical trial of FSD-2...
31 May 2022
FSD Pharma (CSE:HUGE, NASDAQ:HUGE) Inc has announced that it has submitted Investigation New Drug applications to the US Food and Drug Administration (FDA) and Health Canada for its planned Phase 2 cl...
FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such as depressive disorder; and Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. FSD Pharma Inc. was founded in 1998 and is headquartered in Toronto, Canada.
Stock Value >
Financial Summary > Financial Statements > Financial Quarter Statements > Ratios Analysis > Dupont Analysis > Free Cash Flow > Operating Data > Balance Sheet Data >